Vaginal gene therapy

Advanced Drug Delivery Reviews

Volumn 92, Issue , 2015, Pages 71-83

  Rodríguez Gascón, Alicia ^a   del Pozo Rodríguez, Ana ^a   Isla, Arantxazu ^a   Solinís, María Angeles ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Gene therapy; Non viral vectors; Sexually transmitted infections; Vaginal delivery; Viral vectors

Indexed keywords

DISEASE CONTROL; DRUG THERAPY; GENE THERAPY; GENE TRANSFER; NUCLEIC ACIDS; VIRUSES;

FEMALE REPRODUCTIVE TRACT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; NONVIRAL VECTORS; NUCLEIC ACID DELIVERIES; SEXUALLY TRANSMITTED INFECTIONS; VAGINAL DELIVERY; VIRAL VECTORS;

DISEASES;

ADENOVIRUS VECTOR; ANTIFUNGAL AGENT; DENDRIMER; DNA VACCINE; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; LIPID; LIPOSOME; MACROGOL; NANOPARTICLE; PARVOVIRUS VECTOR; POLYMER; PYRROLE DERIVATIVE; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; VIRUS LIKE PARTICLE VACCINE;

BIOCOMPATIBILITY; BIODEGRADABILITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; GENETIC VARIABILITY; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RNA INTERFERENCE; SEXUAL BEHAVIOR; TREATMENT INDICATION; VAGINA CANDIDIASIS; VAGINAL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT; CANDIDIASIS, VULVOVAGINAL; DRUG ABSORPTION; FEMALE; GENE VECTOR; HIV INFECTIONS; INTRAVAGINAL DRUG ADMINISTRATION; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PROCEDURES; SEXUALLY TRANSMITTED DISEASES, VIRAL; THERAPEUTIC USE; VAGINA;

ADMINISTRATION, INTRAVAGINAL; CANDIDIASIS, VULVOVAGINAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HERPES SIMPLEX; HIV INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS; SEXUALLY TRANSMITTED DISEASES, VIRAL; VACCINES, DNA; VAGINA; VAGINAL ABSORPTION;

EID: 84943450217     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.07.002     Document Type: Review

References (125)

1. Hussain A., Ahsan F. The vagina as a route for systemic drug delivery. J. Control. Release 2005, 103:301-313.
2. Baum M.M., Butkyavichene I., Gilman J., Kennedy S., Kopin E., Malone A.M., Nguyen C., Smith T.J., Friend D.R., Clark M.R., Moss J.A. An intravaginal ring for the simultaneous delivery of multiple drugs. J. Pharm. Sci. 2012, 101:2833-2843.
3. Steinbach J. Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs. Cell. Mol. Life Sci. 2015, 72:469-503.
4. Friend D.R. Pharmaceutical development of microbicide drug products. Pharm. Dev. Technol. 2010, 15:562-581.
5. Reflection paper on classification of advanced therapy medicinal products. EMA/CAT/600280/2010 Rev.1 2014, Committee for Advanced Therapies (CAT).
6. Glybera-EMEA/H/C/002145-II/0030 2014, European Medicines Agency.
7. Oliveira C., Silveira I., Veiga F., Ribeiro A.J. Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance. Expert Opin. Drug Deliv. 2015, 12:27-39.
8. Torrecilla J., Rodríguez-Gascón A., Solinís M.A., del Pozo-Rodríguez A. Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed. Res. Int. 2014, 2014:161794. 10.1155/2014/161794.
9. The Journal of Gene Medicine Clinical Trials site (Last accessed January 2015). http://www.wiley.com/legacy/wileychi/genmed/clinical/.
10. Wirth T., Parker N., Ylä-Herttuala S. History of gene therapy. Gene 2013, 525:162-169.
11. Wang B., Boyer J., Srikantan V., Ugen K., Gilbert L., Phan C., Dang K., Merva M., Agadjanyan M.G., Newman M., Carrano R., McCallus D., Coney L., Williams W.V., Weiner D.B. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995, 211:102-112.
12. Rodríguez-Gascón A., del Pozo-Rodríguez A., Solinís M.A. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int. J. Nanomedicine 2014, 9:1833-1843.
13. Bagarazzi M.L., Boyer J.D., Ugen K.E., Javadian M.A., Chattergoon M., Shah A., Bennett M., Ciccarelli R., Carrano R., Coney L., Weiner D.B. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. Vaccine 1998, 16:1836-1841.
14. Palliser D., Chowdhury D., Wang Q.Y., Lee S.J., Bronson R.T., Knipe D.M., Lieberman J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006, 439:89-94.
15. Ensign L.M., Cone R., Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J. Control. Release 2014, 190:500-514.
16. Alexander N.J., Baker E., Kaptein M., Karck U., Miller L., Zampaglione E. Why consider vaginal drug administration?. Fertil. Steril. 2004, 82:1-12.
17. Vanić Ž., Škalko-Basnet N. Nanopharmaceuticals for improved topical vaginal therapy: can they deliver?. Eur. J. Pharm. Sci. 2013, 50:29-41.
18. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
19. Yang S., Chen Y., Ahmadie R., Ho E.A. Advancements in the field of intravaginal siRNA delivery. J. Control. Release 2013, 167:29-39.
20. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1482-1487.
21. Acartürk F. Mucoadhesive vaginal drug delivery systems. Recent Pat. Drug Deliv. Formul. 2009, 3:193-205.
22. El-Hammadi M.M., Arias J.L. Nano-sized platforms for vaginal drug delivery. Curr. Pharm. 2015, 21:1633-1644.
23. Yang M., Lai S.K., Yu T., Wang Y.Y., Happe C., Zhong W., Zhang M., Anonuevo A., Fridley C., Hung A., Fu J., Hanes J. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J. Control. Release 2014, 192:202-208.
24. Ensign L.M., Hoen T.E., Maisel K., Cone R.A., Hanes J.S. Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials 2013, 34:6922-6929.
25. Yu Y.Y.Wang, Yang M., Schneider C., Zhong W., Pulicare S., Choi W.J., Mert O., Fu J., Lai S.K., Hanes J. Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly(lactic-co-glycolic acid). Drug Deliv. Transl. Res. 2012, 2. 10.1007/s13346-011-0048-9.
26. Rohan L.C., Sassi A.B. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009, 11:78-87.
27. Owen D.H., Katz D.F. A vaginal fluid stimulant. Contraception 1999, 59:91-95.
28. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 2005, 57:1692-1712.
29. Hiorth M., Nilsen S., Tho I. Bioadhesive mini-tablets for vaginal drug delivery. Pharmaceutics 2014, 6:494-511.
30. Johansson E.L., Rudin A., Wassen L., Holmgren J. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology 1999, 96:272-277.
31. Kumamoto Y., Iwasaki A. Unique features of antiviral immune system of the vaginal mucosa. Curr. Opin. Immunol. 2012, 24:411-416.
32. Rodríguez-Gascón A., del Pozo-Rodríguez A., Solinís M.A. Non-viral delivery systems in gene therapy. Gene Therapy - Tools and Potential Applications 2013, 3-33. Intech, Rijeka, Croatia. F. Martín Molina (Ed.).
33. Gene Therapy Clinical Trials Worldwide Provided by the Journal of Gene Medicine 2014, Jon Wiley and Sons Ltd., (http://www.wiley.co.k/genmed/clinical (accessed 30 January 2015)).
34. Solinís M.A., del Pozo-Rodríguez A., Apaolaza P.S., Rodríguez-Gascón A. Treatment of ocular disorders by gene therapy. Eur. J. Pharm. Biopharm. 2014, (pii: S0939-6411(14)00377-4). 10.1016/j.ejpb.2014.12.022.
35. Qin B., Shukla R.S., Cheng K. Delivery of nucleic acids for ocular gene modulation. Advances in Ocular Drug Delivery 2012, 87-114. Research Signpost Kerala, India. A.K. Mitra (Ed.).
36. Mohan R.R., Sharma A., Netto M.V., Sinha S., Wilson S.E. Gene therapy in the cornea. Prog. Retin. Eye Res. 2005, 24:537-559.
37. Jager L., Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr. Gene Ther. 2007, 7:272-283.
38. Rajiv R.M., Tovey J.C.K., Sharma A., Tandon A. Gene therapy in the cornea: 2005-present. Prog. Retin. Eye Res. 2012, 31:43-64.
39. Wozniak K.L., Palmer G., Kutner R., Fidel P.L. Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. Med. Mycol. 2005, 43:589-601.
40. Rivera V.M., Gao G.P., Grant R.L., Schnell M.A., Zoltick P.W., Rozamus L.W., Clackson T., Wilson J.M. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005, 105:1424-1430.
41. Enrico M.S., Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vis. Res. 2008, 48:353-359.
42. Abdel-Motal U.M., Sarkis P.T., Han T., Pudney J., Anderson D.J., Zhu Q., Marasco W.A. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One 2011, 6:e26473. 10.1371/journal.pone.0026473.
43. Abdel-Motal U.M., Harbison C., Han T., Pudney J., Anderson D.J., Zhu Q., Westmoreland S., Marasco W.A. Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer. Gene Ther. 2014, 21:802-810.
44. Kuck D., Lau T., Leuchs B., Kern A., Müller M., Gissmann L., Kleinschmidt J.A. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J. Virol. 2006, 80:2621-2630.
45. Molina R.P., Ye H.Q., Brady J., Zhang J., Zimmerman H., Kaleko M., Luo T. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct. Hum. Gene Ther. 2004, 15:865-877.
46. Berkowitz R., Ilves H., Lin W.Y., Eckert K., Coward A., Tamaki S., Veres G., Plavec I. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J. Virol. 2001, 75:3371-3382.
47. Yanez-Munoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., Buch P., MacLaren R.E., Anderson P.N., Barker S.E., Duran Y., Bartholomae C., von Kalle C., Heckenlively J.R., Kinnon C., Ali R.R., Thrasher A.J. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 2006, 12:348-353.
48. Balaggan K.S., Ali R.R. Ocular gene delivery using lentiviral vectors. Gene Ther. 2012, 19:145-153.
49. Williams K.A., Coster D.J. Gene therapy for diseases of the cornea - a review. Clin. Exp. Ophthalmol. 2010, 38:93-103.
50. 4+ T cells. Curr. HIV Res. 2013, 11:56-66.
51. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., MacIntyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118:3132-3142.
52. Herzog R.W. Gene therapy for SCID-X1: round 2. Mol. Ther. 2010, 18:1891.
53. Patel D.H., Misra A. Gene delivery using viral vectors. Challenges in Delivery of Therapeutic Genomics and Proteomics 2011, 207-270. Elsevier, Burlington, MA, USA. A. Misra (Ed.).
54. Huang S., Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnol. Adv. 2013, 31:208-223.
55. Liu Z., Xiang Y., Wei Z., Yu B., Shao Y., Zhang J., Yang H., Li M., Guan M., Wan J., Zhang W. Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpex. J. Virol. Methods 2013, 193:353-358.
56. Elouahabi A., Ruysschaert J.M. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 2005, 11:336-347.
57. Delgado D., Gascón A.R., del Pozo-Rodríguez A., Echevarría E., Ruiz de Garibay A.P., Rodríguez J.M., Solinís M.A. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int. J. Pharm. 2012, 425:35-43.
58. Delgado D., del Pozo-Rodríguez A., Solinís M.A., Bartkowiak A., Rodríguez-Gascón A. New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation. Eur. J. Pharm. Sci. 2013, 50:484-491.
59. Alabi C.A., Love K.T., Sahay G., Yin H., Luly K.M., Langer R., Anderson D.G. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12881-12886.
60. Lin P.J., Tam Y.Y., Hafez I., Sandhu A., Chen S., Ciufolini M.A., Nabi I.R., Cullis P.R. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine 2013, 9:233-246.
61. Mével M., Kamaly N., Carmona S., Oliver M.H., Jorgensen M.R., Crowther C., Salazar F.H., Marion P.L., Fujino M., Natori Y., Thanou M., Arbuthnot P., Yaouanc J.J., Jaffrès P.A., Miller A.D. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J. Control. Release 2010, 143:222-232.
62. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
63. Abul-Hassan K., Walmsley R., Boulton M. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr. Eye Res. 2000, 20:361-366.
64. Mannermaa E., Rönkkö S., Ruponen M., Reinisalo M., Urtti A. Long-lasting secretion of transgene product from differentiated and filter-grown retinal pigment epithelial cells after nonviral gene transfer. Curr. Eye Res. 2005, 30:345-353.
65. Peeters L., Sanders N.N., Braeckmans K., Boussery K., Van de Voorde J., De Smedt S.C., Demeester J. Vitreous: a barrier to nonviral ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 2005, 46:3553-3561.
66. Chen C.W., Yeh M.K., Shiau C.Y., Chiang C.H., Lu D.W. Efficient downregulation of VEGF in retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery. Int. J. Nanomedicine 2013, 8:2613-2627.
67. del Pozo-Rodríguez A., Delgado D., Solinís M.A., Gascón A.R., Pedraz J.L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 2007, 339:261-268.
68. del Pozo-Rodríguez A., Delgado D., Solinís M.A., Gascón A.R. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides. Recent Pat. Drug Deliv. Formul. 2011, 5:214-226.
69. Teeranachaideekul V., Müller R.H., Junyaprasert V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int. J. Pharm. 2007, 340:198-206.
70. Müller R., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
71. del Pozo-Rodríguez A., Solinís M.A., Gascón A.R., Pedraz J.L. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur. J. Pharm. Biopharm. 2009, 71:181-189.
72. Delgado D., del Pozo-Rodríguez A., Solinís M.A., Rodríguez-Gascón A. Understanding the mechanism of protamine in solid lipid nanoparticle based lipofection: the importance of the entry pathway. Eur. J. Pharm. Biopharm. 2011, 79:495-502.
73. del Pozo-Rodríguez A., Pujals S., Delgado D., Solinís M.A., Gascón A.R., Giralt E., Pedraz J.L. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J. Control. Release 2009, 133:52-59.
74. Delgado D., del Pozo-Rodríguez A., Solinís M.A., Avilés-Triqueros M., Weber B.H., Fernández E., Gascón A.R. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum. Gene Ther. 2012, 23:345-355.
75. Apaolaza P.S., Delgado D., del Pozo-Rodríguez A., Gascón A.R., Solinís M.A. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int. J. Pharm. 2014, 465:413-426.
76. Chen H., Chang X., Du D., Liu W., Liu J., Weng T., Yang Y., Xu H., Yang X. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release 2006, 110:296-306.
77. Jayagopal A., Sussman E.M., Shastri V.P. Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans. Nanobioscience 2008, 7:28-34.
78. Alukda D., Sturgis T., Youan B.B. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J. Pharm. Sci. 2011, 100:3345-3356.
79. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 2009, 8:526-533.
80. Wang B., Navath R.S., Menjoge A.R., Balakrishnan B., Bellair R., Dai H., Romero R., Kannan S., Kannanb R.M. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int. J. Pharm. 2010, 395:298-308.
81. Vacas-Córdoba E., Galán M., de la Mata F.J., Gómez R., Pion M., Muñoz-Fernández M.A. Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides. Int. J. Nanomedicine 2014, 9:3591-3600.
82. Sepúlveda-Crespo D., Lorente R., Leal M., Gómez R., De la Mata F.J., Jiménez J.L., Muñoz-Fernández M.A. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 2014, 10:609-618.
83. Tiyaboonchai W., Woiszwillo J., Middaugh C.R. Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur. J. Pharm. Sci. 2003, 19:191-202.
84. Hornof M., de la Fuente M., Hallikainen M., Tammi R.H., Urtti A. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. J. Gene Med. 2008, 10:70-80.
85. de la Fuente M., Seijo B., Alonso M.J. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 2008, 49:2016-2024.
86. Klausner E.A., Zhang Z., Wong S.P., Chapman R.L., Volin M.V., Harbottle R.P. Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free, or S/MAR plasmid DNA. J. Gene Med. 2011, 14:100-108.
87. Nowak J., Laffleur F., Bernkop-Schnürch A. Preactivated hyaluronic acid: a potential mucoadhesive polymer for vaginal delivery. Int. J. Pharm. 2015, 478:383-389.
88. Değim Z., Değim T., Acartürk F., Erdoğan D., Ozoğul C., Köksal M. Rectal and vaginal administration of insulin-chitosan formulations: an experimental study in rabbits. J. Drug Target. 2005, 13:563-572.
89. Fontana D., Kratje R., Etcheverrigaray M., Prieto C. Rabies virus-like particles expressed in HEK293 cells. Vaccine 2014, 32:2799-2804.
90. Zochowska M., Piguet A.C., Jemielity J., Kowalska J., Szolajska E., Dufour J.F., Chroboczek J. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. Nanomedicine 2015, 11:67-76.
91. Connell M., Owen C., Segars J. Genetic syndromes and genes involved in the development of the female reproductive tract: a possible role for gene therapy. J. Genet. Syndr. Gene. Ther. 2013, 4:127.
92. Sobel J.D. Pathogenesis of recurrent vulvovaginal candidiasis. Curr. Infect. Dis. Rep. 2002, 4:514-519.
93. Sobel J.D. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Prefer Adher. 2013, 16:31-34.
94. Zhang J.Y., Liu J.H., Liu F.D., Xia Y.H., Wang J., Liu X., Zhang Z.Q., Zhu N., Yan-Yan Y.Ying, Huang X.T. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses 2014, 57:584-591.
95. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
96. Fidel P.L., Lynch M.E., Sobel J.D. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect. Immun. 1993, 61:4202-4207.
97. Wozniak K.L., Wormley F.L., Fidel P.L. Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect. Immun. 2002, 70:5790-5799.
98. Kemble G., Spaete R. Herpes simplex vaccines. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis 2007, Cambridge University Press, Cambridge, (Chapter 69). A. Arvin, G. Campadelli-Fiume, E. Mocarski, P.S. Moore, B. Roizman, R. Whitley, K. Yamanishi (Eds.).
99. Liu Z., Xiang Y., Wei Z., Yu B., Shao Y., Zhang J., Yang H., Li M., Guan M., Wan J., Zhang W. Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. J. Virol. Methods 2013, 193:353-358.
100. Fleming D.T., McQuillan G.M., Johnson R.E., Nahmias A.J., Aral S.O., Lee F.K., Louis M.E.St Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 1997, 337:1105-1111.
101. Armstrong G.L., Schillinger J., Markowitz L., Nahmias A.J., Johnson R.E., McQuillan G.M., Louis M.E.St Incidence of herpes simplex virus type 2 infection in the United States. Am. J. Epidemiol. 2001, 153:912-920.
102. Arvin A.M., Prober C.G. Herpes simplex virus type 2 - a persistent problem. N. Engl. J. Med. 1997, 337:1158-1159.
103. Wu Y., Navarro F., Lal A., Basar E., Pandey R.K., Manoharan M., Feng Y., Lee S.J., Lieberman J., Palliser D. Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 2009, 5:84-94.
104. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
105. de Sanjosé S., Quint W.C., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., Tous S., Felix A., Bravo L.E., Shin H.R., Vallejos C.S., de Ruiz P.A., Lima M.A., Guimera N., Clavero O., Alejo M., Llombart-Bosch A., Cheng-Yang C., Tatti S.A., Kasamatsu E., Iljazovic E., Odida M., Prado R., Seoud M., Grce M., Usubutun A., Jain A., Suarez G.A., Lombardi L.E., Banjo A., Menéndez C., Domingo E.J., Velasco J., Nessa A., Chichareon S.C., Qiao Y.L., Lerma E., Garland S.M., Sasagawa T., Ferrera A., Hammouda D., Mariani L., Pelayo A., Steiner I., Oliva E., Meijer C.J., Al-Jassar W.F., Cruz E., Wright T.C., Puras A., Llave C.L., Tzardi M., Agorastos T., Garcia-Barriola V., Clavel C., Ordi J., Andújar M., Castellsagué X., Sánchez G.I., Nowakowski A.M., Bornstein J., Muñoz N., Bosch F.X. Retrospective international survey and HPV time trends study group, human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
106. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., Ferlay J. Worldwide burden of cervical cancer in 2008. Ann. Oncol. 2011, 22:2675-2686.
107. Stanley M.A. Genital human papillomavirus infections: current and prospective therapies. J. Gen. Virol. 2012, 93:681-691.
108. Kuck D., Leder C., Kern A., Müller M., Piuko K., Gissmann L., Kleinschmidt J.A. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly. Vaccine 2006, 24:2952-2965.
109. Govan V.A. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann. N. Y. Acad. Sci. 2005, 1056:328-343.
110. Jiang M., Milner J. Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs. Methods Mol. Biol. 2005, 292:401-420.
111. Chen X.Z., Zhu K.J., Xu Y., Tang X.Y., Cai X.Z., Zhang X., Cheng H. RNA interference silences the human papillomavirus 6b/11 early gene E7 in vitro and in vivo. Clin. Exp. Dermatol. 2010, 35:509-515.
112. Reschner A., Bontems S., Le Gac S., Lambermont J., Marcélis L., Defrancq E., Hubert P., Moucheron C., Kirsch-De Mesmaeker A., Raes M., Piette J., Delvenne P. Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53. Gene Ther. 2013, 20:435-443.
113. Date A.A., Destache C.J. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 2013, 34:6202-6228.
114. Levy J.A. HIV and the Pathogenesis of AIDS 2007, Wiley-Blackwell, Hoboken, N.J. third ed.
115. Demberg T., Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol. 2009, 28:20-48.
116. Broliden K., Haase A.T., Ahuja S.K., Shearer G.M., Andersson J. Introduction: back to basics: mucosal immunity and novel HIV vaccine concepts. J. Intern. Med. 2009, 265:5-17.
117. Seay K., Qi X., Zheng J.H., Zhang C., Chen K., Dutta M., Deneroff K., Ochsenbauer C., Kappes J.C., Littman D.R., Goldstein H. Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy. PLoS One 2013, 8. e63537.
118. Symonds G.P., Johnstone H.A., Millington M.L., Boyd M.P., Burke B.P., Breton L.R. The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol. Res. 2010, 48:84-98.
119. Zeller S.J., Kumar P. RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J. Biol. Med. 2011, 84:301-309.
120. Vlachakis D., Tsiliki G., Pavlopoulou A., Roubelakis M.G., Tsaniras S.C., Kossida S. Antiviral stratagems against HIV-1 using RNA interference (RNAi) technology. Evol. Bioinformatics Online 2013, 9:203-213.
121. Wheeler L.A., Trifonova R., Vrbanac V., Basar E., McKernan S., Xu Z., Seung E., Deruaz M., Dudek T., Einarsson J.I., Yang L., Allen T.M., Luster A.D., Tager A.M., Dykxhoorn D.M., Lieberman J. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest. 2011, 121:2401-2412.
122. Mercier G.T., Nehete P.N., Passeri M.F., Nehete B.N., Weaver E.A., Templeton N.S., Schluns K., Buchl S.S., Sastry K.J., Barry M.A. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007, 25:8687-8701.
123. Simpson J.L. Genetics of the female reproductive ducts. Am. J. Med. Genet. 1999, 89:224-239.
124. Lin P.C., Bhatnagar K.P., Nettleton G.S., Nakajima S.T. Female genital anomalies affecting reproduction. Fertil. Steril. 2002, 78:899-915.
125. Grimbizis G.F., Camus M., Tarlatzis B.C., Bontis J.N., Devroey P. Clinical implications of uterine malformations and hysteroscopic treatment results. Hum. Reprod. Update 2001, 7:161-174.